Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes.

Farngren J, Persson M, Ahrén B

Diabetes care4 Nov 2015Cited by 14 (Europe PMC)

PMID26537183DOI10.2337/dc15-1274PepBankPUB-26537183

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In insulin-treated subjects with type 2 diabetes, HbA1c was lower after lixisenatide than placebo.
In plain wordsIn insulin-treated people with diabetes, HbA1c was lower after lixisenatide than placebo.
Peptide
Lixisenatide
Outcome
DecreaseHbA1c
Study
n = 18
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated · 6 weeksAs given in this study (human).
Source sentences
Summary
After 6 weeks of treatment, HbA1c and FBG levels were lower after lixisenatide therapy than after placebo therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects received treatment with lixisenatide or placebo for 6 weeks in random order, with a 4-week washout period in between.
Summary · context
After 6 weeks of treatment, subjects underwent a two-step hyperinsulinemic hypoglycemic clamp at 3.5 and 2.8 mmol/L.
Report a problemFND-2653718301
02HumanRandomized controlled trialEfficacy outcome
In insulin-treated subjects with type 2 diabetes, fasting blood glucose was lower after lixisenatide than placebo.
In plain wordsIn insulin-treated people with diabetes, fasting blood glucose was lower after lixisenatide than placebo.
Peptide
Lixisenatide
Outcome
DecreaseFasting blood glucose
Study
n = 18
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated · 6 weeksAs given in this study (human).
Source sentences
Summary
After 6 weeks of treatment, HbA1c and FBG levels were lower after lixisenatide therapy than after placebo therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects received treatment with lixisenatide or placebo for 6 weeks in random order, with a 4-week washout period in between.
Summary · context
After 6 weeks of treatment, subjects underwent a two-step hyperinsulinemic hypoglycemic clamp at 3.5 and 2.8 mmol/L.
Report a problemFND-2653718302
03HumanRandomized controlled trialEfficacy outcome
In insulin-treated subjects with type 2 diabetes, lixisenatide lowered glucagon versus placebo at glucose 3.5 mmol/L.
In plain wordsIn insulin-treated people with diabetes, lixisenatide lowered glucagon compared with placebo during insulin-induced low blood sugar at 3.5 mmol/L.
Peptide
Lixisenatide
Outcome
DecreaseGlucagon at glucose 3.5 mmol/L
Study
n = 18
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated · 6 weeksAs given in this study (human).
Source sentences
Summary
At the hypoglycemic level of 3.5 mmol/L, glucagon and epinephrine levels were significantly lower during lixisenatide treatment than during placebo treatment, whereas at 2.8 mmol/L glucagon and epinephrine levels did not differ between the subjects.
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects received treatment with lixisenatide or placebo for 6 weeks in random order, with a 4-week washout period in between.
Summary · context
After 6 weeks of treatment, subjects underwent a two-step hyperinsulinemic hypoglycemic clamp at 3.5 and 2.8 mmol/L.
Report a problemFND-2653718303
04HumanRandomized controlled trialEfficacy outcome
In insulin-treated subjects with type 2 diabetes, lixisenatide lowered epinephrine versus placebo at glucose 3.5 mmol/L.
In plain wordsIn insulin-treated people with diabetes, lixisenatide lowered epinephrine compared with placebo during moderate hypoglycemia.
Peptide
Lixisenatide
Outcome
DecreaseEpinephrine at glucose 3.5 mmol/L
Study
n = 18
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated · 6 weeksAs given in this study (human).
Source sentences
Summary
At the hypoglycemic level of 3.5 mmol/L, glucagon and epinephrine levels were significantly lower during lixisenatide treatment than during placebo treatment, whereas at 2.8 mmol/L glucagon and epinephrine levels did not differ between the subjects.
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects received treatment with lixisenatide or placebo for 6 weeks in random order, with a 4-week washout period in between.
Summary · context
After 6 weeks of treatment, subjects underwent a two-step hyperinsulinemic hypoglycemic clamp at 3.5 and 2.8 mmol/L.
Report a problemFND-2653718304
05HumanRandomized controlled trialEfficacy outcome
In insulin-treated subjects with type 2 diabetes, glucagon did not differ between lixisenatide and placebo at glucose 2.8 mmol/L.
In plain wordsIn insulin-treated people with diabetes, glucagon did not differ between lixisenatide and placebo during deep hypoglycemia.
Peptide
Lixisenatide
Outcome
No significant changeGlucagon at glucose 2.8 mmol/L
Study
n = 18
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated · 6 weeksAs given in this study (human).
Source sentences
Summary
At the hypoglycemic level of 3.5 mmol/L, glucagon and epinephrine levels were significantly lower during lixisenatide treatment than during placebo treatment, whereas at 2.8 mmol/L glucagon and epinephrine levels did not differ between the subjects.
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects received treatment with lixisenatide or placebo for 6 weeks in random order, with a 4-week washout period in between.
Summary · context
After 6 weeks of treatment, subjects underwent a two-step hyperinsulinemic hypoglycemic clamp at 3.5 and 2.8 mmol/L.
Report a problemFND-2653718305
06HumanRandomized controlled trialEfficacy outcome
In insulin-treated subjects with type 2 diabetes, epinephrine did not differ between lixisenatide and placebo at glucose 2.8 mmol/L.
In plain wordsIn insulin-treated people with diabetes, epinephrine did not differ between lixisenatide and placebo during deep hypoglycemia.
Peptide
Lixisenatide
Outcome
No significant changeEpinephrine at glucose 2.8 mmol/L
Study
n = 18
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated · 6 weeksAs given in this study (human).
Source sentences
Summary
At the hypoglycemic level of 3.5 mmol/L, glucagon and epinephrine levels were significantly lower during lixisenatide treatment than during placebo treatment, whereas at 2.8 mmol/L glucagon and epinephrine levels did not differ between the subjects.
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects received treatment with lixisenatide or placebo for 6 weeks in random order, with a 4-week washout period in between.
Summary · context
After 6 weeks of treatment, subjects underwent a two-step hyperinsulinemic hypoglycemic clamp at 3.5 and 2.8 mmol/L.
Report a problemFND-2653718306
07HumanRandomized controlled trialEfficacy outcome
In insulin-treated subjects with type 2 diabetes, cortisol did not differ significantly between lixisenatide and placebo.
In plain wordsIn insulin-treated people with diabetes, cortisol did not differ significantly between lixisenatide and placebo.
Peptide
Lixisenatide
Outcome
No significant changeCortisol
Study
n = 18
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated · 6 weeksAs given in this study (human).
Source sentences
Summary
Cortisol, pancreatic polypeptide, and norepinephrine levels did not differ significantly between the treatments.
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects received treatment with lixisenatide or placebo for 6 weeks in random order, with a 4-week washout period in between.
Summary · context
After 6 weeks of treatment, subjects underwent a two-step hyperinsulinemic hypoglycemic clamp at 3.5 and 2.8 mmol/L.
Report a problemFND-2653718307
08HumanRandomized controlled trialEfficacy outcome
In insulin-treated subjects with type 2 diabetes, pancreatic polypeptide did not differ significantly between lixisenatide and placebo.
In plain wordsIn insulin-treated people with diabetes, pancreatic polypeptide did not differ significantly between lixisenatide and placebo.
Peptide
Lixisenatide
Outcome
No significant changePancreatic polypeptide
Study
n = 18
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated · 6 weeksAs given in this study (human).
Source sentences
Summary
Cortisol, pancreatic polypeptide, and norepinephrine levels did not differ significantly between the treatments.
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects received treatment with lixisenatide or placebo for 6 weeks in random order, with a 4-week washout period in between.
Summary · context
After 6 weeks of treatment, subjects underwent a two-step hyperinsulinemic hypoglycemic clamp at 3.5 and 2.8 mmol/L.
Report a problemFND-2653718308
09HumanRandomized controlled trialEfficacy outcome
In insulin-treated subjects with type 2 diabetes, norepinephrine did not differ significantly between lixisenatide and placebo.
In plain wordsIn insulin-treated people with diabetes, norepinephrine did not differ significantly between lixisenatide and placebo.
Peptide
Lixisenatide
Outcome
No significant changeNorepinephrine
Study
n = 18
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated · 6 weeksAs given in this study (human).
Source sentences
Summary
Cortisol, pancreatic polypeptide, and norepinephrine levels did not differ significantly between the treatments.
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects received treatment with lixisenatide or placebo for 6 weeks in random order, with a 4-week washout period in between.
Summary · context
After 6 weeks of treatment, subjects underwent a two-step hyperinsulinemic hypoglycemic clamp at 3.5 and 2.8 mmol/L.
Report a problemFND-2653718309

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02020629

Study on Lixisenatide and Counterregulation to Hypoglycemia

Lund Universityn = 18Dec 2013 to Aug 2015

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 15 Dec 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.